Pretransplant management of end-stage renal disease patients to minimize posttransplant risk

Transplantation

Volumn 70, Issue 11, 2000, Pages

  Jardine, A G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 0034671111     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Long-term survival in renal transplant recipients with graft function
2. Cardiovascular morbidity and risk factors in renal replacement patients
3. Ischemic heart disease - Major cause of death and graft loss after renal transplantation in Scandinavia
4. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation
5. Cardiovascular disease after renal transplantation
6. Early echocardiographic changes and survival following renal transplantation
7. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators
8. Blood pressure lowering for the primary and secondary prevention of stroke: Treatment of hypertension reduces the risk of stroke
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
11. Report on management of renal failure in Europe, XXII, 1991
12. Clinical epidemiology of cardiovascular disease in chronic renal disease
13. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients
14. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada
15. Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis
16. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant
17. Electrocardiogram and outcome following renal transplantation
18. Outcome and risk factors for left ventricular disorders in chronic uraemia
19. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
20. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
21. Clinical and echocardio-graphic disease in patients starting end-stage renal disease therapy
22. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients
23. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure
24. Impact of left ventricular hypertrophy on survival in end-stage renal disease
25. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
26. Association of chronic kidney graft survival with recipient blood pressure
27. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
28. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
29. For the angiotensin-converting enzyme inhibition and progressive renal disease study group
30. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade
31. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy
32. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure
33. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects